Neurological diseases such as Alzheimer's Disease will continue to increase as the population ages. While there are a very drugs on the market that treats the symptoms of these diseases effectively, there currently no drugs on the market that have been identified to cure or reverse these neurological processes. This ongoing translational initiative is a continuation of NIA's Toxicology Contract with SRI International, Investigational new Drug Toxicology for Drugs to Treat Alzheimer's Disease and other Aging-Related Diseases. The purpose of this contract is to evaluate the preclinical safety and pharmacology of potential therapeutics for treatment of Alzheimer's disease and other diseases associated with aging. This contract offers the opportunity and potential to develop new drugs and increase the likelihood of bringing them to the clinic sooner and safer.
